Literature DB >> 11438305

Role of the NMDA receptor subunit in the expression of the discriminative stimulus effect induced by ketamine.

M Narita1, K Yoshizawa, M Nomura, K Aoki, T Suzuki.   

Abstract

Ketamine, which is a non-competitive NMDA receptor antagonist, has been used as a dissociative anesthetic agent. However, chronic use of ketamine produces psychotomimetic effects, such as nightmares, hallucination and delusion. Therefore, the present study was designed to ascertain the role of the NMDA receptor and sigma receptor in the discriminative stimulus effect induced by ketamine. Fischer 344 rats were trained to discriminate between ketamine (5 mg/kg, i.p.) and saline under a fixed-ratio 10 food-reinforced procedure. Non-competitive antagonists for both NR2A- and NR2B-containing NMDA receptors, such as phencyclidine (0.1--1 mg/kg, i.p.) and dizocilpine (3--30 microg/kg, i.p.), and the NR2A-containing NMDA receptor-preferred antagonist dextromethorphan (3--56 mg/kg, i.p.) fully substituted for the ketamine cue in a dose-dependent manner. By contrast, the NR2B-containing NMDA receptor antagonist ifenprodil (5--20 mg/kg, i.p.) exhibited no generalization. Additionally, the competitive NMDA antagonist 3-[(+/-)-2-carboxypiperazine-4-yl] propyl-1-phosphonic acid ((+/-)-CPP; 0.3--5.6 mg/kg, i.p.) and a sigma receptor ligand DTG (0.3--3 mg/kg, s.c.) displayed no generalization to the ketamine cue. These results suggest that NR1/NR2A subunit containing NMDA antagonism may be critical for the production of the ketamine cue.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11438305     DOI: 10.1016/s0014-2999(01)01089-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

2.  Discriminative stimulus effects of NMDA, AMPA, and mGluR5 glutamate receptor ligands in methamphetamine-trained rats.

Authors:  Thomas E Wooters; Linda P Dwoskin; Michael T Bardo
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

Review 3.  Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

Authors:  Adam L Halberstadt
Journal:  Behav Brain Res       Date:  2014-07-15       Impact factor: 3.332

4.  Age-dependent differences in sensitivity and sensitization to cannabinoids and 'club drugs' in male adolescent and adult rats.

Authors:  Jenny L Wiley; Rhys L Evans; Darren B Grainger; Katherine L Nicholson
Journal:  Addict Biol       Date:  2007-09-11       Impact factor: 4.280

5.  The organic cation transporter 3 (OCT3) as molecular target of psychotropic drugs: transport characteristics and acute regulation of cloned murine OCT3.

Authors:  Vivian Massmann; Bayram Edemir; Eberhard Schlatter; Rouvier Al-Monajjed; Saliha Harrach; Philipp Klassen; Svenja K Holle; Aleksandra Sindic; Marina Dobrivojevic; Hermann Pavenstädt; Giuliano Ciarimboli
Journal:  Pflugers Arch       Date:  2013-08-28       Impact factor: 3.657

Review 6.  The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects.

Authors:  Sungho Maeng; Carlos A Zarate
Journal:  Curr Psychiatry Rep       Date:  2007-12       Impact factor: 8.081

7.  Memantine protects thalamocortical hyper-glutamatergic transmission induced by NMDA receptor antagonism via activation of system xc<sup/>.

Authors:  Motohiro Okada; Kouji Fukuyama; Yasuhiro Kawano; Takashi Shiroyama; Yuto Ueda
Journal:  Pharmacol Res Perspect       Date:  2019-01-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.